Section Arrow
PTN.NASDAQ
- Palatin Technologies
Quotes are at least 15-min delayed:2026/10/18 19:14 EDT
Regular Hours
Last
 6.02
-0.47 (-7.24%)
Day High 
6.93 
Prev. Close
6.49 
1-M High
11.73 
Volume 
39.20K 
Bid
5.9
Ask
8.5
Day Low
6 
Open
6.93 
1-M Low
6.35 
Market Cap 
11.56M 
Currency 美元 
P/E 82.91 
%Yield -- 
10-SMA 8.6 
20-SMA 9.21 
50-SMA 9.98 
52-W High 31 
52-W Low 5.61 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.96/-1.25
Enterprise Value
11.62M
Balance Sheet
Book Value Per Share
3.75
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
13.19M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals3.465-0.695-16.71%-- 
TCRTAlaunos Therapeutics Inc.2.63+0.45+20.64%-- 
IBRXImmunityBio9.18-0.82-8.20%-- 
MRNAModerna218.01-18.49-7.82%-- 
SLSSELLAS Life Sciences Group9.98-1.36-11.99%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. It is also developing, dependent on resources for development activities, MC1R agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It has one operating segment life science.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.